All In Biotech

NDA 201373 · Chattem Sanofi

Children'S Allegra Hives

Fexofenadine Hydrochloride · Oral

Last checked: Nov 19, 2026Latest source record: Dec 27, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2011

Jan 24, 2011

Approved uses

1

Original approval plus efficacy supplements

Registered trials

99

15 Phase 3, 7 recruiting

FAERS reports

9,324

5,607 serious, 544 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 1, 2026.

Uses reduces hives and relieves itching due to hives (urticaria). This product will not prevent hives or an allergic skin reaction from occurring.

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 24, 2011 Original approval · Type 8 - Partial Rx to OTC Switch LabelLetterReview
2 products under this application
  • CHILDREN'S ALLEGRA HIVES · FEXOFENADINE HYDROCHLORIDE 30MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SUSPENSION, ORAL · Discontinued
  • CHILDREN'S ALLEGRA ALLERGY · FEXOFENADINE HYDROCHLORIDE 30MG/5ML · SUSPENSION, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Fexofenadine" as an intervention, any sponsor and status, largest first.

All 99 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective868
  • nausea483
  • diarrhoea456
  • headache456
  • fatigue453
  • dizziness406
  • pruritus405
  • dyspnoea385
  • product quality issue359
  • rash350
  • pain286
  • malaise279

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004215
2005206
200677
200761
200882
200988
2010265
2011239
2012206
2013191
2014205
2015383
2016532
2017520
2018535
2019674
2020693
2021677
2022664
2023622
2024653
2025824
2026711

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 267 on PubMed

Sponsor: Chattem Sanofi · Also marketed as Children'S Allegra Allergy

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.